Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.

Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R
Br J Cancer. 2014 Nov 25;111(11):2103-13. doi: 10.1038/bjc.2014.534. Epub 2014 Nov 4. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.